These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 28074293)
21. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke. Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229 [TBL] [Abstract][Full Text] [Related]
22. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465 [TBL] [Abstract][Full Text] [Related]
23. Minimizing the Risk of Bleeding with NOACs in the Elderly. Kundu A; Sardar P; Chatterjee S; Aronow WS; Owan T; Ryan JJ Drugs Aging; 2016 Jul; 33(7):491-500. PubMed ID: 27174293 [TBL] [Abstract][Full Text] [Related]
24. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005 [TBL] [Abstract][Full Text] [Related]
25. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Lee SI; Sayers M; Lip GY; Lane DA Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557 [TBL] [Abstract][Full Text] [Related]
27. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation. Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603 [TBL] [Abstract][Full Text] [Related]
28. [From heparin to apixaban: anticoagulants cut both ways?]. Hartung K; Meyer F; Bock F; Isermann B Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104 [TBL] [Abstract][Full Text] [Related]
29. [Procedures on patients receiving NOACs : What's possible?]. Polzin A; Kelm M; Horn P Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):117-124. PubMed ID: 28074294 [TBL] [Abstract][Full Text] [Related]
30. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Beyer-Westendorf J; Ageno W Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150 [TBL] [Abstract][Full Text] [Related]
31. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions. Pan EY; Sobieraj DM Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982 [No Abstract] [Full Text] [Related]
32. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
33. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing]. Oberhofer E MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289 [No Abstract] [Full Text] [Related]
34. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Stöllberger C; Finsterer J Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425 [TBL] [Abstract][Full Text] [Related]
35. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Undas A; Drabik L; Potpara T Pol Arch Intern Med; 2020 Jan; 130(1):47-58. PubMed ID: 31933483 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091 [TBL] [Abstract][Full Text] [Related]
37. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. Chan KE; Giugliano RP; Patel MR; Abramson S; Jardine M; Zhao S; Perkovic V; Maddux FW; Piccini JP J Am Coll Cardiol; 2016 Jun; 67(24):2888-99. PubMed ID: 27311528 [TBL] [Abstract][Full Text] [Related]
38. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
39. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant? Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507 [TBL] [Abstract][Full Text] [Related]
40. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]